[go: up one dir, main page]

AR045528A2 - Sales de ziprasidona - Google Patents

Sales de ziprasidona

Info

Publication number
AR045528A2
AR045528A2 ARP040103099A ARP040103099A AR045528A2 AR 045528 A2 AR045528 A2 AR 045528A2 AR P040103099 A ARP040103099 A AR P040103099A AR P040103099 A ARP040103099 A AR P040103099A AR 045528 A2 AR045528 A2 AR 045528A2
Authority
AR
Argentina
Prior art keywords
ziprasidona
salts
ziprasidone
silate
tartrate
Prior art date
Application number
ARP040103099A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR045528A2 publication Critical patent/AR045528A2/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Seasonings (AREA)
  • Machine Translation (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una sal caracterizada porque es seleccionada entre esilato de ziprasidona, mesilato de ziprasidona y tartrato de ziprasidona.
ARP040103099A 1996-05-07 2004-08-27 Sales de ziprasidona AR045528A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
AR045528A2 true AR045528A2 (es) 2005-11-02

Family

ID=21791976

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970101854A AR007002A1 (es) 1996-05-07 1997-05-05 Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina
ARP040103099A AR045528A2 (es) 1996-05-07 2004-08-27 Sales de ziprasidona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970101854A AR007002A1 (es) 1996-05-07 1997-05-05 Composicion de una materia conteniendo una sal de aril-heterociclo y una ciclodextrina o una sal de inclusion del mismo en una ciclodextrina

Country Status (47)

Country Link
US (2) US6232304B1 (es)
EP (1) EP0900088B1 (es)
JP (1) JP3579060B2 (es)
KR (1) KR20000010823A (es)
CN (1) CN1216923A (es)
AP (1) AP796A (es)
AR (2) AR007002A1 (es)
AT (1) ATE257714T1 (es)
AU (1) AU713711B2 (es)
BG (3) BG64474B1 (es)
BR (1) BR9709213A (es)
CA (1) CA2251912C (es)
CO (1) CO4600677A1 (es)
CZ (1) CZ297847B6 (es)
DE (1) DE69727218T2 (es)
DK (1) DK0900088T3 (es)
DZ (1) DZ2220A1 (es)
EA (1) EA001731B1 (es)
EG (1) EG24135A (es)
ES (1) ES2212809T3 (es)
GE (1) GEP20074185B (es)
GT (1) GT199700044A (es)
HN (1) HN1997000039A (es)
HR (1) HRP970237B1 (es)
HU (1) HU222451B1 (es)
ID (1) ID16866A (es)
IL (1) IL126546A (es)
IS (1) IS2524B (es)
MA (1) MA24172A1 (es)
ME (1) ME00880B (es)
MY (1) MY121999A (es)
NO (1) NO324373B1 (es)
NZ (1) NZ332220A (es)
OA (1) OA10907A (es)
PL (1) PL189324B1 (es)
PT (1) PT900088E (es)
RS (1) RS49532B (es)
SA (1) SA97180024B1 (es)
SI (1) SI0900088T1 (es)
SK (1) SK282032B6 (es)
TN (1) TNSN97075A1 (es)
TR (1) TR199802231T2 (es)
TW (1) TW514529B (es)
UA (1) UA57734C2 (es)
UY (1) UY24544A1 (es)
WO (1) WO1997041896A2 (es)
ZA (1) ZA973874B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
PT811386E (pt) * 1996-05-07 2004-12-31 Pfizer Metodo de seleccao de um sal para a preparacao de um complexo de inclusao
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
BR0313602A (pt) * 2002-08-20 2005-06-21 Bristol Myers Squibb Co Método e formulação de complexo de aripiprazol
AP2005003250A0 (en) * 2002-09-17 2005-03-31 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
JP2006514923A (ja) * 2002-10-25 2006-05-18 ファイザー・プロダクツ・インク 注射可能な新規なデポ製剤
CN1703198A (zh) * 2002-10-25 2005-11-30 辉瑞产品公司 呈混悬剂形式的芳基杂环活性物质的贮库制剂
JP2006506397A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体及び半固体高分子イオン・コンジュゲート
CA2504345A1 (en) * 2002-10-31 2004-05-13 Pfizer Products Inc. Liquid conjugates of solid pharmaceuticals
MXPA03009945A (es) 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
KR20080093464A (ko) * 2003-09-02 2008-10-21 화이자 프로덕츠 인크. 지프라시돈 나노입자
CA2548491A1 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2006032957A1 (en) * 2004-05-26 2006-03-30 Pfizer Products Inc. In vitro predictive method
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
MX2009000404A (es) 2006-07-10 2009-06-26 Paion Uk Ltd Sales de benzodiazepina de accion corta y sus formas polimorficas.
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
PT811386E (pt) 1996-05-07 2004-12-31 Pfizer Metodo de seleccao de um sal para a preparacao de um complexo de inclusao
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
HU229057B1 (en) 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
EA199800910A1 (ru) 1999-04-29
JPH11509866A (ja) 1999-08-31
AU713711B2 (en) 1999-12-09
UA57734C2 (uk) 2003-07-15
DE69727218T2 (de) 2004-11-18
ME00880B (me) 2006-12-15
AU1937297A (en) 1997-11-26
EP0900088B1 (en) 2004-01-14
DE69727218D1 (de) 2004-02-19
IL126546A0 (en) 1999-08-17
IS4880A (is) 1998-10-27
CZ297847B6 (cs) 2007-04-11
ES2212809T3 (es) 2004-08-01
EP0900088A2 (en) 1999-03-10
BG64474B1 (bg) 2005-04-30
GT199700044A (es) 1998-10-02
NZ332220A (en) 2000-03-27
NO985192L (no) 1998-11-06
HU222451B1 (hu) 2003-07-28
YU17297A (sh) 1999-12-27
AP796A (en) 1999-12-24
BG102894A (en) 1999-09-30
JP3579060B2 (ja) 2004-10-20
ZA973874B (en) 1998-11-06
NO324373B1 (no) 2007-10-01
BG64475B2 (bg) 2005-04-30
DZ2220A1 (fr) 2002-12-03
BR9709213A (pt) 1999-08-10
HRP970237B1 (en) 2002-04-30
CA2251912A1 (en) 1997-11-13
HUP9902799A3 (en) 2000-12-28
IS2524B (is) 2009-07-15
HN1997000039A (es) 1997-06-26
IL126546A (en) 2001-01-28
MY121999A (en) 2006-03-31
CA2251912C (en) 2003-06-03
TNSN97075A1 (fr) 2005-03-15
TR199802231T2 (xx) 1999-02-22
HRP970237A2 (en) 1998-12-31
SK150498A3 (en) 2000-01-18
UY24544A1 (es) 2000-09-29
US20010031756A1 (en) 2001-10-18
OA10907A (en) 2001-10-26
BG64475B1 (bg) 2005-04-30
SI0900088T1 (en) 2004-04-30
ATE257714T1 (de) 2004-01-15
AP9700977A0 (en) 1997-07-31
CZ346198A3 (cs) 1999-09-15
PT900088E (pt) 2004-04-30
GEP20074185B (en) 2007-08-10
WO1997041896A3 (en) 1998-01-08
PL329928A1 (en) 1999-04-26
DK0900088T3 (da) 2004-04-19
WO1997041896A2 (en) 1997-11-13
SK282032B6 (sk) 2001-10-08
EA001731B1 (ru) 2001-08-27
SA97180024B1 (ar) 2005-12-24
HUP9902799A2 (hu) 1999-12-28
KR20000010823A (ko) 2000-02-25
US6399777B2 (en) 2002-06-04
US6232304B1 (en) 2001-05-15
TW514529B (en) 2002-12-21
AR007002A1 (es) 1999-10-13
MA24172A1 (fr) 1997-12-31
PL189324B1 (pl) 2005-07-29
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
CO4600677A1 (es) 1998-05-08
ID16866A (id) 1997-11-20
RS49532B (sr) 2006-12-15
NO985192D0 (no) 1998-11-06

Similar Documents

Publication Publication Date Title
AR045528A2 (es) Sales de ziprasidona
TR199501053A2 (tr) Tedavide yararli spiro-azabisiklik bilesikler.
SI1477063T1 (sl) Sinergisticne herbicidne mesanice vsebujoce sulfonil ureo in dicambo
DE69532942D1 (de) Unabhängige, angetriebene, chirurgische Vorrichtung
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
ZA96937B (en) Substituted benzisoxazole and benzisothiazole herbicidal agents.
NO962952D0 (no) 1,2,4-oksadiazolderivater og deres anvendelse som parasitticider for dyr
ATE279142T1 (de) Bodenbearbeitungsmaschine
TR199600808A1 (tr) Tatlandirici tuzlar.
MX9201643A (es) Agentes contra tumores y anti-psoriasicos.
ITBO910034A1 (it) Dispositivo ad ultrasuoni per la saldatura ed il taglio senza sfrangiatura di stoffe naturali, sintetiche o miste.
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
DE69400004D1 (de) Vorrichtung zum Saugen und Speichern von Abfällen.
BR9909529A (pt) Maleato de paroxetina
NO892893D0 (no) Vevnad for bruk i papirmaskiner.
NO962951L (no) 3-arylalkenyl-1,2,4-oksadiazolderivater og deres anvendelse som parasitticider for dyr
IT242042Y1 (it) Contenitore in ovatta sterile.
ES1027050Y (es) Cepillo dental.
ES1026718Y (es) Billetero porta-documentos perfeccionado.
FR2708417B1 (fr) Appareil pour le déjabotage des volailles.
ITGE940044A0 (it) Dispositivo sterilizzatore per utensili, in particolare di parrucchie-ri, acconciatori, estetisti o simili.
DK0821676T3 (da) 3-Phenyl-1,4-diakyl-1,2,4-triazoliumsalte samt deres anvendelse som antidpressive midler
ITSV950018A0 (it) Utensile chirurgico per interventi in laparoscopia.
IT230707Y1 (it) Carrellino porta-secchi e porta-strizzatore per mop-radazze,per lavori di pulizia in genere.
ES1029078Y (es) Portaflores de solapa.

Legal Events

Date Code Title Description
FC Refusal